NCT05045313View on ClinicalTrials.gov

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions

Healthy Subjects

Interventions

DRUG

Warfarin sodium tablets

Drug: Warfarin sodium, tablet, oral

DRUG

Digoxin tablet

Drug: Digoxin, tablet, oral

DRUG

Probenecid tablets

Drug: Probenecid, tablet, oral

DRUG

DBPR108 tablets

Drug: DBPR108, tablet, oral

Trial Locations (1)

Unknown

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05045313 - A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects | Biotech Hunter | Biotech Hunter